- Home
- NAMI vs HURA Comparison
NAMI vs HURA Comparison
Compare NAMI & HURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NAMI
- HURA
- Stock Information
- Founded
- NAMI 2014
- HURA 2009
- Country
- NAMI China
- HURA United States
- Employees
- NAMI N/A
- HURA N/A
- Industry
- NAMI
- HURA
- Sector
- NAMI
- HURA
- Exchange
- NAMI NYSE
- HURA Nasdaq
- Market Cap
- NAMI 185.3M
- HURA 171.7M
- IPO Year
- NAMI 2024
- HURA N/A
- Fundamental
- Price
- NAMI $1.05
- HURA $2.26
- Analyst Decision
- NAMI
- HURA Strong Buy
- Analyst Count
- NAMI 0
- HURA 2
- Target Price
- NAMI N/A
- HURA $11.50
- AVG Volume (30 Days)
- NAMI 74.2K
- HURA 401.7K
- Earning Date
- NAMI 08-11-2025
- HURA 08-15-2025
- Dividend Yield
- NAMI N/A
- HURA N/A
- EPS Growth
- NAMI N/A
- HURA N/A
- EPS
- NAMI 0.10
- HURA N/A
- Revenue
- NAMI $55,677,960.00
- HURA N/A
- Revenue This Year
- NAMI N/A
- HURA N/A
- Revenue Next Year
- NAMI N/A
- HURA $69.15
- P/E Ratio
- NAMI $10.64
- HURA N/A
- Revenue Growth
- NAMI 7.00
- HURA N/A
- 52 Week Low
- NAMI $0.97
- HURA $1.80
- 52 Week High
- NAMI $7.75
- HURA $13.13
- Technical
- Relative Strength Index (RSI)
- NAMI N/A
- HURA N/A
- Support Level
- NAMI N/A
- HURA N/A
- Resistance Level
- NAMI N/A
- HURA N/A
- Average True Range (ATR)
- NAMI 0.00
- HURA 0.00
- MACD
- NAMI 0.00
- HURA 0.00
- Stochastic Oscillator
- NAMI 0.00
- HURA 0.00
About NAMI JINXIN TECHNOLOGY HOLDING COMPANY SPONSORED ADS EACH REP 18 ORD SHS
Jinxin Technology Holding Co is a company which operates through its subsidiaries are principally engaged in provision of digital textbook subscription services in the People's Republic of China. The company generates revenue by selling its content to hardware manufacturers in China whereby are allowed to install the company's digital educational content on the manufacturers' devices for sale to end users.
About HURA TuHURA Biosciences Inc. Common Stock
TuHURA Biosciences Inc is a Phase 3 registration stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. The company's personalized cancer vaccine candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. It is preparing to initiate a single randomized placebo-controlled Phase 3 registration trial of IFx-2.0 administered as an adjunctive therapy to Keytruda (pembrolizumab) in first-line treatment for advanced or metastatic Merkel Cell Carcinoma.